Tumors depend on their microenvironment for sustained growth, invasion, and
metastasis. In this environment, endothelial cells (ECs) are an important stromal cell type interacting with malignant cells to facilitate
tumor angiogenesis and
cancer cell extravasation. Of note,
lysosomal acid lipase (
LAL) deficiency facilitates
melanoma growth and
metastasis. ECs from LAL-deficient (lal-/-) mice possess enhanced proliferation, migration, and permeability of inflammatory cells by activating the
mammalian target of rapamycin (mTOR) pathway. Here we report that lal-/- ECs facilitated in vivo
tumor angiogenesis, growth, and
metastasis, largely by stimulating
tumor cell proliferation, migration, adhesion, and transendothelial migration via increased expression of
IL-6 and
monocyte chemoattractant protein 1 (MCP-1). This prompted us to look for
lysosomal proteins that are involved in lal-/- EC dysfunctions. We found that lal-/- ECs displayed increased expression of Rab7, a late endosome/lysosome-associated
small GTPase. Moreover, Rab7 and mTOR were co-increased and co-localized to lysosomes and physically interacted in lal-/- ECs. Rab7 inhibition reversed lal-/- EC dysfunctions, including decreasing their enhanced migration and permeability of
tumor-stimulatory myeloid cells, and suppressed EC-mediated stimulation of in vitro
tumor cell transmigration, proliferation, and migration and in vivo
tumor growth and
metastasis. Finally, Rab7 inhibition reduced overproduction of
reactive oxygen species and increased
IL-6 and MCP-1 secretion in lal-/- ECs. Our results indicate that metabolic reprogramming resulting from
LAL deficiency enhances the ability of ECs to stimulate
tumor cell proliferation and
metastasis through stimulation of lysosome-anchored Rab7 activity.